
|Videos|August 6, 2021
FDA Delays Impacting Inflammatory Skin Disease Community
Author(s)Morgan Petronelli
Mark Lebwohl, MD, explains the recent delay in approval of JAK inhibitors by the FDA, how it is affecting the inflammatory skin disease community, and if physicians should be concerned.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Reviewing Type 2 Inflammation Through a Different Lens
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5


















